

Global Life Sciences Fund A2 HCNH

Fund facts at 31 January 2021 Date of issue: 26 February 2021

Structure

Irish Investment Company

Fund launch date

31 March 2000

Fund size (USD)

4.02bn

Benchmark

MSCI World Health Care

Fund managers

Andy Acker, CFA

Share class launch date

03 October 2014

NAV (CNH)

21.82

Maximum initial charge

5.00%

Annual management charge (AMC)

1.50% pa

Ongoing charge AMC included

2.35%

Performance fee

N/A

Trading frequency

Daily

Ex-dividend date (XD)

N/A

Pay date

N/A

Codes

ISIN: IE00BFTCP959

Sedol: BFTCP95

Product classification

Equity

Objective and investment policy

The Fund aims to provide capital growth over the long term.

The Fund invests at least 80% of its assets in shares (also known as equities) selected for their growth potential and with a life sciences orientation. The Fund may invest in companies of any size, in any country.

Additional information


Effective 6 July 2020, the naming convention of the Classes of Shares of the Fund has been changed. Please refer to the offering documents for more details.

Information relating to other currencies and fee structure can be found in the fund prospectus.

Refer to the Annual Report and Accounts for more information on ongoing charge AMC included.

Performance in (CNH)

Percentage growth, 31 Jan 2016 to 31 Jan 2021.



Source: at 31 Jan 2021. © 2021 Morningstar. All rights reserved, performance is on a net of fees basis, with gross income reinvested.

Cumulative performance % change	A2 (Net)	Benchmark	Calendar year returns %	A2	Benchmark
1 month	-1.0	1.8	2020	24.6	12.3
3 months	15.0	12.7	2019	27.1	23.8
YTD	-1.0	1.8	2018	3.0	5.5
1 year	27.0	14.4	2017	24.7	19.7
3 years	49.7	43.1	2016	-9.5	-4.7
5 years	104.9	85.4			
Since inception (Inception date: 03 Oct 2014)	118.2	103.1			

Source: at 31 Jan 2021. © 2021 Morningstar. All rights reserved, performance is on a net of fees basis, with gross income reinvested.

Source: at 31 Dec 2020. © 2021 Morningstar. All rights reserved, performance is on a net of fees basis, with gross income reinvested.

The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Past performance is not a guide to future performance. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.

See next page for breakdowns and risks.

Global Life Sciences Fund A2 HCNH

(continued)

Top 10 holdings	(%)	Industry breakdown	(%)	Market capitalisation	(%)
AstraZeneca PLC	3.7	Biotechnology	32.9	Over \$100B	36.2
UnitedHealth Group Inc	3.4	Pharmaceuticals	31.2	\$50B to \$100B	11.8
AbbVie Inc	3.1	Health Care Equipment	14.5	\$10B to \$50B	21.2
Merck & Co Inc	3.0	Managed Health Care	8.0	\$5B to \$10B	9.8
Novartis AG (ADR)	2.9	Life Sciences Tools & Services	6.5	\$1B to \$5B	13.1
Roche Holding AG	2.9	Health Care Supplies	3.8	\$500M to \$1B	1.3
Abbott Laboratories	2.5	Health Care Technology	1.1	\$250M to \$500M	0.2
Thermo Fisher Scientific Inc	2.5	Health Care Services	0.9	N/A	5.6
Eli Lilly and Co	2.3	Health Care Facilities	0.2		
Boston Scientific Corp	2.3	Specialized Finance	0.1		
Total number of positions	129				

What are the risks specific to this fund?

- The Fund could lose money if a counterparty with which it trades becomes unwilling or unable to meet its obligations to the Fund.
- Shares can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result.
- Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses.
- If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified.
- The Fund is focused towards particular industries or investment themes and may be heavily impacted by factors such as changes in government regulation, increased price competition, technological advancements and other adverse events.
- The Fund may use derivatives with the aim of reducing risk or managing the portfolio more efficiently. However this introduces other risks, in particular, that a derivative counterparty may not meet its contractual obligations.
- If the Fund holds assets in currencies other than the base currency of the Fund or you invest in a share class of a different currency to the Fund (unless 'hedged'), the value of your investment may be impacted by changes in exchange rates.

General risks

- Past performance is not a guide to future performance.
- The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.
- Tax assumptions and reliefs depend upon an investor's particular circumstances and may be subject to change.

For further information please visit our website at www.janushenderson.com/cn

Global Life Sciences Fund A2 HCNH

(continued)

Important information

Source: Janus Henderson Investors. For hedged share classes the appropriate index is the hedged version of the mandated benchmark. Only share class returns are displayed as we do not currently subscribe to this index. Please note: due to rounding the figures in the holdings breakdowns may not add up to 100%. The content is for information purposes only and should not be used or construed as investment, legal or tax advice, or as an offer to sell, a solicitation of an offer to buy, or a recommendation to buy, sell or hold any security, investment strategy or market sector. Nothing in this material shall be deemed to be a direct or indirect provision of investment management services specific to any client requirement. No forecasts can be guaranteed and there is no guarantee that the information supplied is complete or timely, nor are there any warranties with regard to the results obtained from its use. Janus Henderson is the source of data unless otherwise indicated, and has reasonable belief to rely on information and data sources from third parties. **Past performance is no guarantee of future results. Investing involves risk, including the possible loss of principal and fluctuation of value.**

Not all products or services are available in all jurisdictions. This material or information contained in it may be restricted by law, and may not be reproduced or referred to without express written permission or used in any jurisdiction or circumstance in which its use would be unlawful. Janus Henderson is not responsible for any unlawful distribution of this material to any third parties, in whole or in part. The contents have not been approved or endorsed by any regulatory agency.

Portfolio holdings are subject to change without notice.

Janus Henderson Capital Funds Plc is a UCITS established under Irish law, with segregated liability between funds. Investors are warned that they should only make their investments based on the most recent Prospectus which contains information about fees, expenses and risks, which is available from all distributors and paying agents, it should be read carefully. An investment in the fund may not be suitable for all investors and is not available to all investors in all jurisdictions; it is not available to US persons. The rate of return may vary and the principal value of an investment will fluctuate due to market and foreign exchange movements. Shares, if redeemed, may be worth more or less than their original cost.

Note to PRC Readers: Janus Henderson is not licensed, authorised or registered with the China Securities Regulatory Commission for investment management or investment consultancy business or otherwise approved by any PRC regulatory authorities to provide investment management or investment consultancy services in the People's Republic of China (the "PRC") (which, for such purposes, does not include the Hong Kong or Macau Special Administrative Regions or Taiwan). The information contained herein has not been, and will not be, submitted to, reviewed by, approved by, verified by, registered or filed with any PRC regulatory bodies and the use of the content shall be limited to the extent permitted by applicable laws, regulations and relevant requirements. Janus Henderson makes no representation and warranties that it is, and will be, in compliance with PRC laws. Nothing in the information contained herein shall be deemed or construed as providing investment management or investment consultancy services by Janus Henderson in the PRC, nor shall it be will viewed as investment advice in relation to PRC capital markets, securities and mutual funds, which may require Janus Henderson to obtain or be subject to any approval, licensing, filing, registration, or other qualification requirements of the relevant Chinese regulatory authorities. The information contained herein is being provided on a confidential basis solely for the information of those persons to whom it is given. This document and the information contained in it is only available to select targeted institutional investors in the PRC.

No invitation to offer, or offer for, or sale of, the fund will be made in the PRC whether publicly or non-publicly or by any means under the PRC laws (whether publicly or non-publicly). The information relating to the fund contained in the offering documents has not been, and will not be, submitted to, reviewed by, approved by, verified by, registered or filed with any PRC regulatory bodies. The Fund may only be offered or sold to PRC investors that are authorized to buy and sell securities denominated in foreign exchange. PRC investors are responsible for obtaining all required governmental approvals, permits, verification, licenses and registration (if any) from all competent governmental authorities before purchasing the fund.

This document and the information contained in it is only available to institutional investors with QDII licence. Not for public distribution or use in the PRC. This document is provided upon request of duly licensed commercial banks in China under the mechanism of Qualified Domestic Institutional Investors ("QDII Bank") for their QDII products.

Janus Henderson is a trademark of Janus Henderson Group plc or one of its subsidiaries. © Janus Henderson Group plc.

In case of discrepancies between the English and Simplified Chinese versions, the English version shall prevail.

KH0121(40T)1221.PRC.QDII